Jacob (Jake) Whitt is an associate in the New York office of Latham & Watkins.

Dr. Whitt represents pharmaceutical and biotechnology companies in all phases of patent litigation from pre-suit investigation through appeal. His experience includes matters arising out of the Biologics Price Competition and Innovation Act (BPCIA) and the Hatch-Waxman Act for biologic and small molecule innovators, respectively. Dr. Whitt also represents clients in IPR and PGR proceedings before the US Patent Trial and Appeal Board.

Dr. Whitt maintains an active pro bono practice, representing individuals in immigration matters, including those seeking asylum.

Before becoming a lawyer, Dr. Whitt researched protein-nucleic acid interactions involved in RNA-based genetic engineering platforms.

 


Dr. Whitt's experience includes advising:

  • Amgen in multiple disputes regarding the blockbuster Neupogen® and Neulasta® biologic drug products against multiple biosimilar manufacturers under the BPCIA.*
  • Sanofi in Hatch-Waxman litigation regarding the chemotherapeutic Jevtana® drug product.*

*Matter handled prior to joining Latham

Bar Qualification

  • New York

Education

  • JD, Tulane University Law School, 2015
    magna cum laude, Order of the Coif
  • PhD in Biochemistry, University of Texas at Austin, 2011
  • BS in Biochemistry, University of Texas at Austin, 2004